Stock Ratings / Health Care / TNGX / dividends

ABCL (44) ARQT (54) LQDA (36) OGN (70) ⌘ Pro Terminal →

Tango Therapeutics Inc. (TNGX) Dividend Safety Gauge & 10-Year DRIP Compounder

$22.72 +0.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $22.71

Tango Therapeutics Inc. (TNGX) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $3.83B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TNGX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TNGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Tango Therapeutics Inc. (NASDAQ: TNGX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $22.72 (+0.84% 1D, market cap $3.83B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TNGX ranks #359 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TNGX compare to ABCL and ARQT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TNGX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.9%. By comparison, ABCL (AbCellera Biologics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -20.5%, cap $3.97B) and ARQT (Arcutis Biotherapeutics Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -3.0%, cap $4.03B). Among the 5-stock peer group, OGN leads on earnings multiple (19.4x) while OGN leads on capital efficiency (24.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TNGX?

▼

Per TNGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001819133), Tango Therapeutics Inc. generated $62.4M in revenue (+48.3% YoY), -$101.6M in net income, and -$139.9M in free cash flow against $398.7M in total assets and $23.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $22.71 (-0.04%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TNGX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY TNGX SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (31% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (24% of score)

FRED Regime × Technicals: 57% of 52W Range • RSI-14 at 46.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$22.19+21.6% Next Q

Q2 (-2Q)

Grade D$26.98-17.6% Next Q

Q3 (-1Q)

Grade D$22.23+2.2% Next Q

Current

Grade D$22.72-6.3% Hist 90D α

Trajectory: E (37) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TNGX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TNGX currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.50) and Max Pain ($23.86) forces dealer call-delta covering toward $36.11.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TNGX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TNGX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.5K

Yr 1

$13.2K

Yr 2

$15.2K

Yr 3

$17.6K

Yr 4

$20.2K

Yr 5

$23.3K

Yr 6

$26.8K

Yr 7

$30.8K

Yr 8

$35.5K

Yr 9

$40.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TNGX)

✓Walkthrough of TNGX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TNGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.04%📐 HORIZONTAL RANGE

2026-11-03O $22.53H $22.72L $22.53C $22.72VOL 5.28M

RES: $28.20SUP: $20.48SMA50: $23.50SMA200: $22.48

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TNGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TNGX Butterfly Map → + Track TNGX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

21.4%/yr Implied 5Y Growth

vs. +48.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TNGX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TNGX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TNGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TNGX)

Health Care Rank #359 of 1016 ⚔️ ABCL vs TNGX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TNGX vs. ABCL, ARQT, LQDA, OGN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Tango Therapeutics Inc. (TNGX) ranks #359 by composite RQD confidence (45/100, grade D) and #185 by equity capitalization ($3.83B). Within this direct 5-issuer industry benchmark cohort, OGN leads on earnings valuation at 19.4x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. OGN currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with TNGX at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TNGX ACTIVE Tango Therapeutics Inc.	D	45/100	—	—	-28.9%	+0.84%	$3.83B	Benchmark Subject
ABCL AbCellera Biologics Inc.	D	44/100	—	—	-20.5%	-6.19%	$3.97B	/abcl-vs-tngx →
ARQT Arcutis Biotherapeutics Inc.	D+	54/100	—	90.2%	-3.0%	+0.31%	$4.03B	/arqt-vs-tngx →
LQDA Liquidia Corporation	D-	36/100	—	—	-12.6%	+0.16%	$4.03B	/lqda-vs-tngx →
OGN Organon & Co.	B-	70/100	19.4x	53.3%	24.9%	+0.22%	$3.63B	/ogn-vs-tngx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001819133

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tango Therapeutics Inc. (TNGX) reported GAAP revenue of $62.4M (+48.3% vs. FY2024 revenue of $42.1M , and +70.8% cumulative change since FY2023) , GAAP net income of -$101.6M, operating cash flow of -$138.9M, and free cash flow of -$139.9M (-5.8% YoY). On the balance sheet, TNGX closed FY2025 with $398.7M in total assets against $23.6M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$62.4M	-$101.6M	-$138.9M	-$139.9M	$398.7M	$23.6M
FY2024 (FY)	2024-12-31	$42.1M	-$130.3M	-$131.5M	-$132.3M	$316.5M	$52.6M
FY2023 (FY)	2023-12-31	$36.5M	-$101.7M	-$118.0M	-$119.6M	$2.09B	$488.9M

3. TNGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TNGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does TNGX compare to ABCL and ARQT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for TNGX?

Where is TNGX trading relative to its 50-day, 200-day, and 52-week technical levels?

TNGX last traded at $22.72 (+0.84% on volume of 5,279,477 shares), positioning the stock -3.32% below its 50-day simple moving average ($23.50) and +1.07% above its 200-day simple moving average ($22.48). Across its 52-week range of $7.37 to $34.39, TNGX sits at the 56.8% percentile with a 14-day RSI of 46.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($19.88 to $25.56).

TNGX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does TNGX pay a dividend and is it safe?

Tango Therapeutics Inc. (TNGX) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: TNGX RQD Cockpit TNGX 12M Forecast TNGX Earnings & Move TNGX Dividends & DRIP TNGX Insiders & 13F TNGX Whale Options TNGX Profit Sankey TNGX News & Why

ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

TNGX — Tango Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:22:50Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, TNGX scores 44 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

Fundamental Cash Engine: 5 / 20. Per the RQD rating, this reflects ROIC of -28.9% and an FCF yield of -3.68%. The reported FY 2025 free cash flow of $-139.9M shows the business is consuming cash rather than generating it.
Whale 13F Flow: 9 / 20. Per the RQD rating, this reflects institutional accumulation and options positioning. The underlying holder detail is not provided in the holders section (see Analyst View).
Insider Conviction: 5 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow scored weakly.
Macro Regime Fit: 11 / 20. Per the RQD rating, this reflects a beta of 0.87 and sector sensitivity.
Forensic Balance Sheet: 14 / 20. Per the RQD rating, this reflects Altman Z 26, Piotroski F 5/9, and Debt/Equity 0.06. This is the strongest pillar, though it is still not a high score.

For a prospective investor evaluating the stock today, the rating points to a cash-burn profile. Operating margin is -60% and the company reports negative EPS (TTM) of -0.6. The balance-sheet pillar offers some comfort on solvency, but the cash-engine and insider-conviction pillars weigh the score down. The forward P/E of 28 is presented alongside negative trailing earnings, so the valuation depends on future earnings that the source data does not project. The rating is an analytical scoring output, not a recommendation.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$62.4M	$-111.3M	$-101.6M	N/A	$-139.9M	$112.3M	$23.6M
FY 2024	$42.1M	$-145.6M	$-130.3M	N/A	$-132.3M	$69.5M	$52.6M
FY 2023	$36.5M	$-114.2M	$-101.7M	N/A	$-119.6M	N/A	$488.9M

Per the SEC financials, revenue grew from $36.5M (FY 2023) to $62.4M (FY 2025), while operating losses persisted in every period shown. Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -28.9%. Per the RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 5/9. Debt fell from $488.9M (FY 2023) to $23.6M (FY 2025), and reported cash was $112.3M at FY 2025, indicating a stronger balance sheet than the prior year despite ongoing cash burn.

Recent Catalysts & News Wire Analysis

Per the recent news section, headlines reference pancreatic cancer data, a JPMorgan rating reiteration ahead of ESMO data, comparisons to Revolution's results, updated vopimetostat combination data, a stock that has run 252%, and a report that the stock traded lower after cancer drug data. Each item is tagged YELLOW under the MARKET WIRE impact label. Per the Butterfly graph, there are no proprietary signals and no supply-chain links. Risk watch items include the trading-lower reaction to data and the valuation concern raised in the "fully valued" headline.

Open Questions

What specific products and clinical programs does Tango Therapeutics commercialize, and what generates its $62.4M of FY 2025 revenue?
What is the source of the reported 252% run and the 52-week range move from $7.37 to $34.39?
What is the cash runway given FY 2025 free cash flow of $-139.9M against reported cash of $112.3M?
What are the institutional and insider holdings behind the 9/20 whale-flow and 5/20 insider-conviction pillar scores?
What trailing P/E and EV/EBITDA apply, given both are absent from the source data?

TNGX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Tango Therapeutics Inc. (TNGX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TNGX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 16h ago

Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In?

Yahoo Finance report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 19h ago

JPMorgan reiterates Tango Therapeutics stock rating ahead of ESMO data

Investing.com report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investor's Business Daily • 22h ago

How Tango Improved On Revolution's 'Unprecedented' Results

Investor's Business Daily report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetostat Combination Data and Regis

Seeking Alpha report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Tango Therapeutics (TNGX) Stock Looks Fully Valued After A 252% Run

Yahoo Finance report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?

Benzinga report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Titan • 1d ago

Tango Therapeutics (TNGX) executive exercises options at $5.20 and sells 27,000 shares

Stock Titan report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Quiver Quantitative • 1d ago

Why Tango Therapeutics Shares Are Falling Today | TNGX Stock News

Quiver Quantitative report covering Tango Therapeutics Inc. (TNGX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TNGX Bull vs. Bear Conversation Board — What's Your Call at $22.72?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TNGX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $19.83 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is TNGX (D • RQD 44/100) a Buy at $22.53?

Welcome to the TNGX (Tango Therapeutics Inc.) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $18.93 (-16.0%)

Spot @ $22.53

Pump the brakes on TNGX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on TNGX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Tango Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $27.94 (+24.0%)

Spot @ $22.53

TNGX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on TNGX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $22.53 (52-wk range $7.37 - $34.39), any beat on forward guidance forces shorts and underweight funds to chase.